Nct00105300

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

Anti-TNF therapy for paediatric IBD: The Scottish national

Anti-TNF therapy for paediatric IBD: The Scottish national

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Efficacy of adalimumab in sarcoidosis patients who developed

Efficacy of adalimumab in sarcoidosis patients who developed

Crohn's disease

Crohn's disease

Sequential use of biologics in the treatment of moderate-to-severe

Sequential use of biologics in the treatment of moderate-to-severe

Expanded adipose-derived stem cells for the treatment of complex

Expanded adipose-derived stem cells for the treatment of complex

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

A British Society of Paediatric Gastroenterology, Hepatology and

A British Society of Paediatric Gastroenterology, Hepatology and

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Clinical experience with infliximab and adalimumab in a single

Clinical experience with infliximab and adalimumab in a single

Management of loss of response to anti-TNF drugs: Change the dose or

Management of loss of response to anti-TNF drugs: Change the dose or

Identification of inflammatory mediators in patients with Crohn's

Identification of inflammatory mediators in patients with Crohn's

Use of a third anti-TNF after failure of two previous anti-TNFs in

Use of a third anti-TNF after failure of two previous anti-TNFs in

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Loss of Response and Need for Adalimumab Dose Intensification in

Loss of Response and Need for Adalimumab Dose Intensification in

The future of inflammatory bowel disease management: Combining

The future of inflammatory bowel disease management: Combining

Comprehensive review: Antitumor necrosis factor agents in

Comprehensive review: Antitumor necrosis factor agents in

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Interleukin-15 and Its Soluble Receptor Mediate the Response to

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in

Vedolizumab: an 4 7 integrin antagonist for ulcerative colitis and

Vedolizumab: an 4 7 integrin antagonist for ulcerative colitis and

Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic

Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic

The CHOICE trial: Adalimumab demonstrates safety, fistula healing

The CHOICE trial: Adalimumab demonstrates safety, fistula healing

Efficacy and safety of adalimumab for the Crohn's disease: A

Efficacy and safety of adalimumab for the Crohn's disease: A

Crohn's disease pharmascape cv

Crohn's disease pharmascape cv

Early Inflammatory Bowel Disease: Different Treatment Response to

Early Inflammatory Bowel Disease: Different Treatment Response to

PDF) Adalimumab in clinical practice  Outcome in 70 rheumatoid

PDF) Adalimumab in clinical practice Outcome in 70 rheumatoid

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing

Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing

Older Age Is Associated with Higher Rate of Discontinuation of Anti

Older Age Is Associated with Higher Rate of Discontinuation of Anti

Efficacy and safety of adalimumab versus infliximab in patients

Efficacy and safety of adalimumab versus infliximab in patients

Anti-TNF-alpha treatment strategies: results and clinical

Anti-TNF-alpha treatment strategies: results and clinical

Psoriasis pharmascape cv

Psoriasis pharmascape cv

Systematic review: The short-term and long-term efficacy of

Systematic review: The short-term and long-term efficacy of

Monitoring Functional Serum Antitumor Necrosis Factor Antibody Level

Monitoring Functional Serum Antitumor Necrosis Factor Antibody Level

Are clinical trial data shared sufficiently today? Yes | The BMJ

Are clinical trial data shared sufficiently today? Yes | The BMJ

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is

Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is

A British Society of Paediatric Gastroenterology, Hepatology and

A British Society of Paediatric Gastroenterology, Hepatology and

Anti-TNF therapy for paediatric IBD: The Scottish national

Anti-TNF therapy for paediatric IBD: The Scottish national

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Systematic review with network meta-analysis: The efficacy of anti

Systematic review with network meta-analysis: The efficacy of anti

Crohn's disease pharmascape cv

Crohn's disease pharmascape cv

Adalimumab induction and maintenance therapy for ulcerative colitis

Adalimumab induction and maintenance therapy for ulcerative colitis

The Benefit-to-Risk Balance of Combining Infliximab With

The Benefit-to-Risk Balance of Combining Infliximab With

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

Retrospective Evaluation of the Safety and Effect of Adalimumab

Retrospective Evaluation of the Safety and Effect of Adalimumab

Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel

Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel

Antisense inhibition of ICAM-1 expression as therapy provides

Antisense inhibition of ICAM-1 expression as therapy provides

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Efficacy and Safety Profile of Anti-Tumor Necrosis Factor-α Versus

Efficacy and Safety Profile of Anti-Tumor Necrosis Factor-α Versus

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current

Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current

Cost-effectiveness of biological treatment sequences for fistulising

Cost-effectiveness of biological treatment sequences for fistulising

Performance of Crohn's disease Clinical Trial Endpoints based upon

Performance of Crohn's disease Clinical Trial Endpoints based upon

Antisense inhibition of ICAM-1 expression as therapy provides

Antisense inhibition of ICAM-1 expression as therapy provides

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Adalimumab is effective in long-term real life clinical practice in

Adalimumab is effective in long-term real life clinical practice in

Long-term safety and efficacy of certolizumab pegol in the treatment

Long-term safety and efficacy of certolizumab pegol in the treatment

Adalimumab safety in global clinical trials of patients with Crohn's

Adalimumab safety in global clinical trials of patients with Crohn's

Optimizing drug therapy in inflammatory bowel disease | Arun

Optimizing drug therapy in inflammatory bowel disease | Arun

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Crohn's disease pharmascape cv

Crohn's disease pharmascape cv

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

Efficacy and safety of adalimumab in patients with psoriasis

Efficacy and safety of adalimumab in patients with psoriasis

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

A Test-based Strategy Is More Cost Effective Than Empiric Dose

A Test-based Strategy Is More Cost Effective Than Empiric Dose

Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel

Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Advances in the management of inflammatory bowel disease | F Grimpen

Advances in the management of inflammatory bowel disease | F Grimpen

The tolerance and efficacy of a postponed retreatment with

The tolerance and efficacy of a postponed retreatment with

Efficacy and safety of adalimumab for the Crohn's disease: A

Efficacy and safety of adalimumab for the Crohn's disease: A

Adalimumab is effective in long-term real life clinical practice in

Adalimumab is effective in long-term real life clinical practice in

Biologics in General Medicine | J  Salfeld | Request PDF

Biologics in General Medicine | J Salfeld | Request PDF

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Antibodies Against Infliximab Are Associated with De Novo

Antibodies Against Infliximab Are Associated with De Novo

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Expanded adipose-derived stem cells for the treatment of complex

Expanded adipose-derived stem cells for the treatment of complex

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Vedolizumab as a Rescue Therapy for Patients with Medically

Vedolizumab as a Rescue Therapy for Patients with Medically

PDF) [Adalimumab in Crohn's disease - data from real life]

PDF) [Adalimumab in Crohn's disease - data from real life]

Genetic Markers Predict Primary Non-Response and Durable Response To

Genetic Markers Predict Primary Non-Response and Durable Response To

Efficacy and complications of adalimumab treatment for medically

Efficacy and complications of adalimumab treatment for medically

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Open-Label Study of Adalimumab in Patients with Ulcerative Colitis

Open-Label Study of Adalimumab in Patients with Ulcerative Colitis

Selecting appropriate anti-TNF agents in inflammatory bowel disease

Selecting appropriate anti-TNF agents in inflammatory bowel disease

Systematic review with network meta-analysis: The efficacy of anti

Systematic review with network meta-analysis: The efficacy of anti

Health-economic analysis: Cost-effectiveness of scheduled

Health-economic analysis: Cost-effectiveness of scheduled

Retrospective Evaluation of the Safety and Effect of Adalimumab

Retrospective Evaluation of the Safety and Effect of Adalimumab

Efficacy and safety of adalimumab versus infliximab in patients

Efficacy and safety of adalimumab versus infliximab in patients